Patents by Inventor Karl K. Johe

Karl K. Johe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100034784
    Abstract: The present invention provides a group of compounds found to increase the number of neurons derived from stem cells for use as a therapeutic agent in neurological conditions or diseases. In one embodiment of the present invention, the compounds are used to detect the mechanism by which the number of neurons is increased.
    Type: Application
    Filed: July 9, 2009
    Publication date: February 11, 2010
    Applicant: NEURALSTEM, INC.
    Inventors: Judith KELLEHER-ANDERSSON, Karl K. JOHE
  • Publication number: 20090297486
    Abstract: The present invention provides methods and compositions for treating spinal cord diseases and injuries. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue.
    Type: Application
    Filed: December 21, 2006
    Publication date: December 3, 2009
    Inventors: Vassilis E. Koliatsos, Jun Yan, Karl K. Johe
  • Publication number: 20090263901
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Application
    Filed: April 15, 2009
    Publication date: October 22, 2009
    Applicant: NeuralStem Biopharmaceuticals, Ltd.
    Inventors: Renji Yang, Karl K. Johe
  • Patent number: 7560553
    Abstract: The present invention provides a group of compounds found to increase the number of neurons derived from stem cells for use as a therapeutic agent in neurological conditions or diseases. In one embodiment of the present invention, the compounds are used to detect the mechanism by which the number of neurons is increased.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: July 14, 2009
    Assignee: Neuralstem, Inc.
    Inventors: Judith Kelleher-Andersson, Karl K. Johe
  • Patent number: 7544511
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: June 9, 2009
    Assignee: Neuralstem Biopharmaceuticals Ltd.
    Inventors: Renji Yang, Karl K. Johe
  • Publication number: 20040185429
    Abstract: A method for discovering neurogenic drugs is revealed. The method allows for systematic screening of test agents such as libraries of compounds. The method consists of exposing test agents to cultures of differentiating neural progenitor cells and measuring their effects on increasing the overall cell number and/or the number of neurons.
    Type: Application
    Filed: December 5, 2003
    Publication date: September 23, 2004
    Inventors: Judith Kelleher-Andersson, Karl K. Johe
  • Publication number: 20030190618
    Abstract: A method for generating five prime biased tandem tag libraries of cDNAs is revealed. The method allows generation of partial sequences consisting of a minimal length of expressed cDNA sequences of at least 20 bases from biological samples to rapidly identify novel expressed transcripts.
    Type: Application
    Filed: March 6, 2002
    Publication date: October 9, 2003
    Inventors: Babru Samal, Yuan Li, Leandro C. Hermida, Nancy L. Hoppa, Karl K. Johe
  • Publication number: 20020064873
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Application
    Filed: January 14, 2002
    Publication date: May 30, 2002
    Inventors: Renji Yang, Karl K. Johe
  • Patent number: 6284539
    Abstract: The present invention describes a novel method to direct a particular set of fate choice decisions by multipotential precursor cells from the central nervous system. Specifically we show that introducing the gene coding for the nuclear receptor, Nurr1, into central nervous system (CNS) stem cells causes cells to adopt a dopaminergic cell fate. One use of this technology would be to prepare in vitro neural populations enriched in dopaminergic cells for transplantation in Parkinson's Disease or other neurological disorders. Furthermore, the finding that Nurr1 expression induces a dopaminergic phenotype suggests that introducing this gene into the brains of patients in which dopaminergic cells are degenerating or have been injured may promote the functional recovery of these neurons and thus the clinical recovery of the patient. Finally, the technology described in this application could be incorporated into a program of drug screening or gene discovery.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: September 4, 2001
    Assignee: NeuralStem Biopharmaceuticals, Ltd.
    Inventors: David C. Bowen, Karl K. Johe
  • Patent number: 6040180
    Abstract: The present invention reveals in vitro cultures of region-specific, terminally differentiated, mature neurons derived from cultures of mammalian multipotential CNS stem cells and an in vitro procedure by which the differentiated neurons may be generated. The procedure involves the culturing of multipotential CNS stem cells from a specific region in a chemically defined serum-free culture medium containing a growth factor; replacing the medium with growth factor-free medium; harvesting the stem cells by trypsinization; plating the stem cells at a density of between 100,000 to 250,000 cells per square centimeter; and culturing the stem cells in a glutamic acid-free chemically defined serum-free culture medium.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: March 21, 2000
    Assignee: NeuralStem Biopharmaceuticals, Ltd.
    Inventor: Karl K. Johe
  • Patent number: 5753506
    Abstract: The present invention reveals an in vitro procedure by which a homogeneous population of multipotential precursor cells from mammalian embryonic neuroepithelium (CNS stem cells) can be expanded up to 10.sup.9 fold in culture while maintaining their multipotential capacity to differentiate into neurons, oligodendrocytes, and astrocytes. Chemically defined conditions are presented that enable a large number of neurons, up to 50% of the expanded cells, to be derived from the stem cells. In addition, four factors--PDGF, CNTF, LIF, and T3--have been identified which, individually, generate significantly higher proportions of neurons, astrocytes, or oligodendrocytes. These defined procedures permit a large-scale preparation of the mammalian CNS stem cells, neurons, astrocytes, and oligodendrocytes under chemically defined conditions with efficiency and control. These cells should be an important tool for many cell- and gene-based therapies for neurological disorders.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: May 19, 1998
    Assignee: CNS Stem Cell Technology, Inc.
    Inventor: Karl K. Johe